Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIK NASDAQ:LMAT NASDAQ:SIBN NASDAQ:SRDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIKAnika Therapeutics$14.95$14.74$7.87▼$16.24$198.53M0.16135,609 shs14,448 shsLMATLeMaitre Vascular$101.82+1.0%$109.23$78.35▼$118.01$2.33B0.6217,025 shs44,958 shsSIBNSiBone$14.81+0.3%$13.33$11.48▼$21.89$658.55M0.67663,451 shs137,149 shsSRDXSurmodics$42.98+0.4%$37.58$25.87▼$43.00$614.53M1.3269,318 shs5.34 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIKAnika Therapeutics+0.27%+2.82%-6.56%+43.47%+22.64%LMATLeMaitre Vascular+3.62%-0.80%-11.83%+12.97%+18.95%SIBNSiBone+4.24%+27.13%+4.76%-3.21%-25.42%SRDXSurmodics0.00%0.00%0.00%0.00%+50.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIKAnika Therapeutics$14.95$14.74$7.87▼$16.24$198.53M0.16135,609 shs14,448 shsLMATLeMaitre Vascular$101.82+1.0%$109.23$78.35▼$118.01$2.33B0.6217,025 shs44,958 shsSIBNSiBone$14.81+0.3%$13.33$11.48▼$21.89$658.55M0.67663,451 shs137,149 shsSRDXSurmodics$42.98+0.4%$37.58$25.87▼$43.00$614.53M1.3269,318 shs5.34 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIKAnika Therapeutics+0.27%+2.82%-6.56%+43.47%+22.64%LMATLeMaitre Vascular+3.62%-0.80%-11.83%+12.97%+18.95%SIBNSiBone+4.24%+27.13%+4.76%-3.21%-25.42%SRDXSurmodics0.00%0.00%0.00%0.00%+50.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIKAnika Therapeutics 2.00Hold$17.0013.71% UpsideLMATLeMaitre Vascular 2.75Moderate Buy$112.6011.67% UpsideSIBNSiBone 2.71Moderate Buy$23.0055.83% UpsideSRDXSurmodics 1.33SellN/AN/ACurrent Analyst Ratings BreakdownLatest LMAT, SRDX, ANIK, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026SIBNSiBone TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $18.005/12/2026SIBNSiBone Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00 ➝ $18.005/6/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/6/2026LMATLeMaitre Vascular Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$105.00 ➝ $120.005/6/2026LMATLeMaitre Vascular Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$118.00 ➝ $127.005/6/2026LMATLeMaitre Vascular Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$94.00 ➝ $104.004/15/2026SIBNSiBone Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $20.004/13/2026LMATLeMaitre Vascular Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/31/2026LMATLeMaitre Vascular Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/10/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)2/27/2026ANIKAnika Therapeutics Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $17.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIKAnika Therapeutics$116.26M1.71N/AN/A$9.95 per share1.50LMATLeMaitre Vascular$256.28M8.99$3.01 per share33.53$17.35 per share5.81SIBNSiBone$200.93M3.26N/AN/A$4.09 per share3.61SRDXSurmodics$120.80M5.09$0.49 per share87.04$8.33 per share5.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIKAnika Therapeutics-$10.88M-$0.79N/AN/AN/A-9.52%-5.90%-4.52%7/29/2026 (Estimated)LMATLeMaitre Vascular$57.73M$2.7137.2130.832.7024.35%15.36%9.78%8/4/2026 (Estimated)SIBNSiBone-$18.90M-$0.39N/AN/AN/A-8.10%-9.56%-7.06%8/3/2026 (Estimated)SRDXSurmodics-$11.54M-$1.23N/A53.73N/A-14.59%-2.99%-1.99%N/ALatest LMAT, SRDX, ANIK, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026SIBNSiBone-$0.17-$0.10+$0.07-$0.10$51.16 million$52.59 million5/5/2026Q1 2026LMATLeMaitre Vascular$0.66$0.68+$0.02$0.68$66.67 million$66.55 million4/29/2026Q1 2026ANIKAnika Therapeutics-$0.07$0.27+$0.34-$0.37$28.14 million$29.61 million2/26/2026Q4 2025ANIKAnika Therapeutics$0.02$0.31+$0.29$0.12$28.88 million$30.62 million2/25/2026Q4 2025LMATLeMaitre Vascular$0.67$0.68+$0.01$0.68$62.98 million$64.45 million2/23/2026Q4 2025SIBNSiBone-$0.13-$0.04+$0.09-$0.04$56.26 million$56.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIKAnika TherapeuticsN/AN/AN/AN/AN/ALMATLeMaitre Vascular$1.000.99%+16.05%36.90%14 YearsSIBNSiBoneN/AN/AN/AN/AN/ASRDXSurmodicsN/AN/AN/AN/AN/ALatest LMAT, SRDX, ANIK, and SIBN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2026LMATLeMaitre Vascularquarterly$0.250.89%5/21/20265/21/20266/4/20262/19/2026LMATLeMaitre Vascularquarterly$0.250.94%3/12/20263/12/20263/26/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIKAnika TherapeuticsN/A4.463.37LMATLeMaitre Vascular0.4214.3212.20SIBNSiBone0.209.998.34SRDXSurmodics0.273.913.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIKAnika Therapeutics91.53%LMATLeMaitre Vascular84.64%SIBNSiBone98.11%SRDXSurmodics96.63%Insider OwnershipCompanyInsider OwnershipANIKAnika Therapeutics12.08%LMATLeMaitre Vascular7.40%SIBNSiBone3.90%SRDXSurmodics8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIKAnika Therapeutics30013.31 million11.70 millionOptionableLMATLeMaitre Vascular49022.85 million21.16 millionOptionableSIBNSiBone35044.35 million42.62 millionOptionableSRDXSurmodics45014.30 million13.03 millionOptionableANIK, LMAT, SRDX, and SIBN HeadlinesRecent News About These CompaniesSurmodics Completes Transition to Private OwnershipFebruary 7, 2026 | newscase.comNBiocoat Announces Formation of Surmodics Services & Technologies Division Following Merger and Divestiture TransactionsDecember 10, 2025 | finance.yahoo.comSurModics Completes Merger, Ends Credit AgreementNovember 19, 2025 | tipranks.comSurmodics stock rises after FTC indicates no appeal of merger rulingNovember 17, 2025 | za.investing.comSurmodics’ acquisition will not be appealed by FTCNovember 17, 2025 | msn.comSurmodics gains as FTC won't appeal denial of GTCR deal injunctionNovember 17, 2025 | msn.comSurmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire TodayNovember 17, 2025 | businesswire.comBarrington Research Downgrades Surmodics (SRDX)November 15, 2025 | msn.comSurModics Merger with GTCR LLC Clears Legal HurdleNovember 12, 2025 | tipranks.comSurmodics Shares Skyrocket 50% After Court Rejects FTC Request to Block GTCR AcquisitionNovember 11, 2025 | msn.comGTCR can proceed with Surmodics acquisition after court denies FTC’s attempt to block itNovember 11, 2025 | massdevice.comSurmodics surges after court denies injunction to block sale to GTCRNovember 11, 2025 | msn.comFederal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC ChallengeNovember 11, 2025 | benzinga.comSurmodics confirms District Court denies request for preliminary injunctionNovember 11, 2025 | msn.comUS judge rejects FTC's bid to block private equity medical company dealNovember 10, 2025 | reuters.comSurmodics sale to GTCR approved by federal courtNovember 10, 2025 | msn.comSurmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCRNovember 10, 2025 | businesswire.comSurmodics’ Pounce Thrombectomy Platform Evaluated in Sex-Specific Analysis of PROWL RegistryNovember 8, 2025 | evtoday.comESurmodics’ Pounce thrombectomy platform shows efficacy in limb ischemia studyNovember 4, 2025 | msn.comSurmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia PresentationsNovember 4, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANIK, LMAT, SRDX, and SIBN Company DescriptionsAnika Therapeutics NASDAQ:ANIK$14.95 0.00 (0.00%) As of 11:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.LeMaitre Vascular NASDAQ:LMAT$101.82 +0.99 (+0.98%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.SiBone NASDAQ:SIBN$14.81 +0.05 (+0.31%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Surmodics NASDAQ:SRDXSurmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings Rewiring AI: NextEra Energy Sparks a Mega Merger Flipping the Switch: Is Ford the Next Big Energy Stock? Does Nano Nuclear Energy’s New Deal Amp the Outlook? Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade? Why Trump’s Amazon Stock Sale May Not Matter at All Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
